PLOS ONE:他汀或影响患者攻击行为?

2015-07-08 大鹏 译 医学论坛网

最新研究显示,除了常规降血脂作用,他汀很可能影响了患者的攻击行为。相关论文发表于2015年6月份《公共科学图书馆期刊》(PLOS ONE)杂志。研究者指出,男性患者在服用他汀后攻击行为会减少,而女性患者服用后作用恰好相反,表现出更多的攻击行为。该研究第一作者Beatrice Golomb博士表示,“这点对于医生及患者而言都有指导意义,一般而言,如果患

最新研究显示,除了常规降血脂作用,他汀很可能影响了患者的攻击行为。相关论文发表于2015年6月份《公共科学图书馆期刊》(PLOS ONE)杂志。

研究者指出,男性患者在服用他汀后攻击行为会减少,而女性患者服用后作用恰好相反,表现出更多的攻击行为。

该研究第一作者Beatrice Golomb博士表示,“这点对于医生及患者而言都有指导意义,一般而言,如果患者出现行为变化,我会优先考虑药物治疗的问题。”

该研究旨在证实血液胆固醇低水平及他汀会影响患者的暴力行为。共入组了1000例成年男性患者及绝经女性患者,随机分为接受他汀治疗或安慰剂治疗,随访时间为6个月,随访内容为患者过往一周内的攻击行为情况。

已往研究显示,血液胆固醇低水平可增加患者攻击行为,但在暴力死亡、暴力犯罪及自杀等事件方面存在双向作用。

造成性别差异的原因和机制

该研究显示,女性患者在服用他汀似乎更容易出现攻击行为,这点在45岁绝经女性患者尤为明显,而且患者基线攻击行为水平越低,这种升高幅度越明显。而多数男性服用他汀后则表现为攻击行为减少。

Beatrice Golomb博士认为,他汀-激素作用影响了攻击行为,他汀一方面能“降睾酮水平、改善细胞能量代谢”从而降低攻击行为,而他汀对5 -羟色胺水平的作用干扰了患者睡眠,或增加其攻击行为——几个攻击行为增多的男患者确实存在服药后睡眠障碍。而激素和神经递质是调节脑部功能的主要因素。

但有心理学专家表示,该研究入组患者基线攻击行为水平过低,这影响了研究结果的实际应用意义,且研究样本量有待提高(该研究计划入组2400例,但随访有效数据仅有1000例)。

总体来说,该研究得出的结论还值得人们继续探索。

原始出处:

Dennis Thompson.Do Cholesterol Drugs Affect Aggression? HealthDay, July 1, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789694, encodeId=98611e89694a2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 07 21:12:00 CST 2015, time=2015-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33863, encodeId=c03c3386313, content=张知识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:01:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32693, encodeId=451d3269373, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Jul 14 07:16:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31764, encodeId=9cc031e6404, content=这都可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31558, encodeId=e2773155898, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789694, encodeId=98611e89694a2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 07 21:12:00 CST 2015, time=2015-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33863, encodeId=c03c3386313, content=张知识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:01:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32693, encodeId=451d3269373, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Jul 14 07:16:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31764, encodeId=9cc031e6404, content=这都可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31558, encodeId=e2773155898, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-30 shenyifeiyang

    张知识!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1789694, encodeId=98611e89694a2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 07 21:12:00 CST 2015, time=2015-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33863, encodeId=c03c3386313, content=张知识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:01:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32693, encodeId=451d3269373, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Jul 14 07:16:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31764, encodeId=9cc031e6404, content=这都可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31558, encodeId=e2773155898, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-14 保守主义

    好吧

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1789694, encodeId=98611e89694a2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 07 21:12:00 CST 2015, time=2015-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33863, encodeId=c03c3386313, content=张知识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:01:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32693, encodeId=451d3269373, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Jul 14 07:16:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31764, encodeId=9cc031e6404, content=这都可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31558, encodeId=e2773155898, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-09 owlhealth

    这都可以

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1789694, encodeId=98611e89694a2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Aug 07 21:12:00 CST 2015, time=2015-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33863, encodeId=c03c3386313, content=张知识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:01:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32693, encodeId=451d3269373, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Jul 14 07:16:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31764, encodeId=9cc031e6404, content=这都可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Jul 09 07:23:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31558, encodeId=e2773155898, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:09:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-08 huaxipanxing

    看看

    0

相关资讯

Euroanaesthesia 2015:他汀控制CABG术后死亡率作用更优

2015年欧洲麻醉会议(Euroanaesthesia)收录了一项临床试验报告,其研究结果显示,心脏冠状动脉旁路移植(CABG)术前他汀治疗可以显著降低患者死亡率,而且这种效果是其他几种常用心血管药物所不具备的。该研究发表于《欧洲麻醉学杂志》(European Journal of Anaesthesiology)。术前心血管药物治疗可以影响围手术期一系列风险指标。他汀已被证实可以降低CABG围手

Stroke:脑出血患者是否应该服用他汀类药物?

有关ICH患者使用他汀类药物一直存在争议。近期,美国心脏学会和美国卒中学会(AHA/ASA)于《卒中》(Stroke)杂志发布了新版脑出血(ICH)管理指南,或许该指南相关内容能初步解答上述问题。在预防ICH复发方面,指南推荐,尚缺乏足够证据限制ICH患者服用他汀类药物(Ⅱb,C)。以下为该指南制定此项指导意见的相关证据。        SPARC

BMJ:降脂药物降低70岁以上老年人中风风险

在高收入国家,越来越多的老年人出现心血管疾病。目前大多数关于降低心血管事件风险的药物的临床研究的参与者都是70岁以下,因此对于大于70岁的老年人该类药物的作用尚不明确。近期Alpérovitch A等人将关于该问题的探究结果发表在了近期《BMJ》上。该研究探究了对于没有已知的心血管事件既往史的老年人,使用降脂药物(他汀类或贝特类)对其冠心病和中风的长期风险的影响。研究者于1999-2000年,在三

老年人他汀应用中国共识:避免盲目应用大剂量

人老了,相对就脆弱了,有临床医生对老年人使用他汀药物的安全有效性有一种担忧。看看由胡大一、赵水平等专家组成的血脂异常老年人使用他汀类药物中国专家共识组制定的共识怎么说。  老年人血脂异常特点  流行病学调查结果显示,随着年龄增加,总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)水平也逐渐增加。  与欧美国家相比,我国老年人的TC、LDL-C和TG平均水平均低于西方人群,以轻、中

JACC:空腹甘油三酯可作为他汀治疗后CVD的预测指标

近期Gregory Schwartz博士研究团队完成了两个主要临床试验的数据析因分析。研究结果显示,对于服用他汀的急性冠脉综合征(ACS)患者,空腹甘油三酯水平升高与患者心血管事件风险率升高存在显著相关性,而且这种相关性在短期随访与长期随访过程中均得到了证实。研究论文发表于《美国心脏病学会杂志》。 研究者在此次研究中分析了MIRACL试验及dal-

BMJ:降脂治疗可减少老年人卒中发生率达30%

法国学者在无已知血管事件的老年人中研究了降脂药物(他汀或贝特类)与冠心病和卒中长期风险的关系,结果表明,他汀或贝特类药物可减少上述人群30%的卒中发生率。相关论文5月19日在线发表于《英国医学杂志》(简称BMJ)杂志。研究者们随机纳入了居住在法国3个城市社区人群7484例,年龄≥65岁(平均年龄73.9岁),女性占63%,入组时受试者均无无已知血管事